Stockscreener 앱 받기
0.58
0.07%
-0.0004
시간 외 거래:
.57
-0.01
-1.72%
전일 마감가:
$0.5804
열려 있는:
$0.5804
하루 거래량:
222.70K
Relative Volume:
0.33
시가총액:
$19.38M
수익:
-
순이익/손실:
$-19.73M
주가수익비율:
-0.2796
EPS:
-2.0742
순현금흐름:
$-16.94M
1주 성능:
+3.57%
1개월 성능:
+26.09%
6개월 성능:
-29.27%
1년 성능:
-27.14%
1일 변동 폭
$0.57
$0.5926
1주일 범위
$0.55
$0.595
52주 변동 폭
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
명칭
Pasithea Therapeutics Corp
전화
(702) 514-4174
주소
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.58 | 15.70M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - globenewswire.com
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView
Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance - TipRanks
Pasithea Therapeutics Received Notice of Noncompliance - TradingView
Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting - Stock Titan
Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest ReadingLow Growth Earnings - Vinanet
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView
KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView
Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan
Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView
Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics (KTTA) Jumps 14% as Price Approaches Key ResistanceMotive Wave - dars.gov.et
Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan
Pasithea Therapeutics Corp. Revenue Breakdown – BOATS:KTTAW - TradingView
Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48TRIN Signal - vinanet.vn
Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net
Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan
Pasithea Therapeutics Corp (KTTA) Cash Flow - TradingKey
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KTTA|Pasithea Therapeutics Corp|Price:0.452|Chg%:-0.003 - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp. Revenue Breakdown – NASDAQ:KTTA - TradingView
KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025 - TradingKey
Pasithea Therapeutics (KTTA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceAnnual Report - po-news-eg.net
Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 - Investing News Network
Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr
Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr
Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
Pasithea Therapeutics Announces Presentation of PAS-004 - GlobeNewswire
New Strong Buy Stocks for July 20th - Yahoo Finance
Kartik Krishnan Net Worth (2026) - GuruFocus
Pasithea Therapeutics (KTTA) Tests Support Zone as Modest Decline ContinuesSmart Beta Flow - vinanet.vn
Pasithea Therapeutics (KTTA) Edges Lower as Stock Hovers Near Support ZoneDay Trade Opportunities - dars.gov.et
Pasithea Therapeutics to present at B. Riley Mi... - Pluang
Pasithea management to meet investors at B. Riley health summit in Boston - Stock Titan
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewswire
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrowing Losses Surprise, But Stock Slips on Revenue AbsenceEBITDA Analysis - dars.gov.et
KTTA Q1 2026 Earnings: Shares Surge on Better-Than-Expected Loss and Operational ProgressRevenue Growth Outlook - dars.gov.et
Pasithea Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock SurgeTax Rate Impact - dars.gov.et
Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView
Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK
Pasithea Therapeutics Corp (KTTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pasithea Therapeutics Corp 주식 (KTTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STEINMAN LAWRENCE | Director |
Nov 28 '25 |
Buy |
0.75 |
133,333 |
100,000 |
199,691 |
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
0.86%
0.31%
자본화:
|
볼륨(24시간):